Erez Raphael - Jan 13, 2023 Form 4 Insider Report for DarioHealth Corp. (DRIO)

Role
Chief Executive Officer, Director
Signature
/s/ Erez Raphael
Stock symbol
DRIO
Transactions as of
Jan 13, 2023
Transactions value $
-$7,449
Form type
4
Date filed
1/18/2023, 04:01 PM
Previous filing
May 20, 2022
Next filing
May 8, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DRIO Common Stock Sale -$7.45K -1.2K -0.11% $6.21 1.11M Jan 13, 2023 Direct F1, F2
holding DRIO Common Stock 37.9K Jan 13, 2023 By Dicilyon Consulting and Investment Ltd. F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 2, 2022.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.20 to $6.23, inclusive. The Reporting Person undertakes to provide to DarioHealth Corp. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2).
F3 The amount shown represents the beneficial ownership of the issuer's securities held by Dicilyon Consulting and Investment Ltd. which may be deemed to be attributable to Mr. Raphael because Mr. Raphael possesses voting and dispositive power over the securities held by Dicilyon Consulting and Investment Ltd. by virtue of a proxy. Mr. Raphael disclaims beneficial ownership of the securities set forth herein.